Cargando…
The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials
BACKGROUND: In recent years, with the enormous advances in the field of cardiac intervention technology, the survival rate of patients with acute myocardial infarction (AMI) has been improved significantly. However, the risk of arrhythmias and heart failure remains very high in AMI patients for long...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494254/ https://www.ncbi.nlm.nih.gov/pubmed/31008964 http://dx.doi.org/10.1097/MD.0000000000015256 |
_version_ | 1783415240196620288 |
---|---|
author | Zhang, Yuqin Wu, Jiani Guo, Shuwen Lin, Wangou Zhang, Binyue Chen, Xi Mo, Hanrong Zhan, Tianwei |
author_facet | Zhang, Yuqin Wu, Jiani Guo, Shuwen Lin, Wangou Zhang, Binyue Chen, Xi Mo, Hanrong Zhan, Tianwei |
author_sort | Zhang, Yuqin |
collection | PubMed |
description | BACKGROUND: In recent years, with the enormous advances in the field of cardiac intervention technology, the survival rate of patients with acute myocardial infarction (AMI) has been improved significantly. However, the risk of arrhythmias and heart failure remains very high in AMI patients for long-term prognosis. Chinese herbal medicine (CHM) is more and more used in the treatment of AMI because of its good curative effect and less side effects. The target of this research is to analyze the efficacy and safety of Astragalus (Huangqi) preparation in the treatment of AMI by meta-analysis and also to provide a better evidence for clinical practice. METHODS: Seven databases will be searched in this study: The Cochrane Library, PubMed, Web of Science, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (CSJD), the Chinese Biomedical Literature Database (CBM), and Wanfang DATA. The following search terms will be used: (Huangqi OR Huang Qi OR Astragalus OR radix astragali) AND (acute myocardial infaction OR myocardial infaction OR AMI) AND (randomized controlled trial OR RCT OR randomized). No language limitations and the searches will be conducted up to March, 2019. Inclusion criteria: randomized controlled trial (RCT) of Astragalus (Huangqi) preparation in patients with AMI. Main outcome measures will be left ventricular end systolic volume (LVESV), left ventricular end diastolic volume (LVEDV), left ventricular ejection fraction (LVEF), left ventricular mass index (LVMI), recanalization rate, mortality rate, incidence of reperfusion arrhythmias, postinfarction angina pectoris, and re-infarction rate. Secondary outcome indicators were the incidence of adverse reactions and the effective rate of traditional Chinese medicine (TCM) treatment. Two independent reviewers will filter the literature and extract data which based to the Cochrane manual. The relevant data, including bias risk assessment, data synthesis, subgroup analysis, meta-analysis, and final meta-analysis, will be analyzed with RevMan 5.3 software. The funnel diagram will be used to evaluate the reported deviation, and the Egger test will be used to evaluate the symmetry of the funnel graph. RESULTS: This systematic review study will provide a clear basis for evaluating the efficacy and safety of Astragalus (Huangqi) preparation with the treatment of AMI. CONCLUSION: This study will provide an up-to-date evidence for evaluating the efficacy and safety of Astragalus (Huangqi) preparation. PROSPERO REGISTRATION NUMBER: CRD42019124843. |
format | Online Article Text |
id | pubmed-6494254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-64942542019-05-29 The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials Zhang, Yuqin Wu, Jiani Guo, Shuwen Lin, Wangou Zhang, Binyue Chen, Xi Mo, Hanrong Zhan, Tianwei Medicine (Baltimore) Research Article BACKGROUND: In recent years, with the enormous advances in the field of cardiac intervention technology, the survival rate of patients with acute myocardial infarction (AMI) has been improved significantly. However, the risk of arrhythmias and heart failure remains very high in AMI patients for long-term prognosis. Chinese herbal medicine (CHM) is more and more used in the treatment of AMI because of its good curative effect and less side effects. The target of this research is to analyze the efficacy and safety of Astragalus (Huangqi) preparation in the treatment of AMI by meta-analysis and also to provide a better evidence for clinical practice. METHODS: Seven databases will be searched in this study: The Cochrane Library, PubMed, Web of Science, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (CSJD), the Chinese Biomedical Literature Database (CBM), and Wanfang DATA. The following search terms will be used: (Huangqi OR Huang Qi OR Astragalus OR radix astragali) AND (acute myocardial infaction OR myocardial infaction OR AMI) AND (randomized controlled trial OR RCT OR randomized). No language limitations and the searches will be conducted up to March, 2019. Inclusion criteria: randomized controlled trial (RCT) of Astragalus (Huangqi) preparation in patients with AMI. Main outcome measures will be left ventricular end systolic volume (LVESV), left ventricular end diastolic volume (LVEDV), left ventricular ejection fraction (LVEF), left ventricular mass index (LVMI), recanalization rate, mortality rate, incidence of reperfusion arrhythmias, postinfarction angina pectoris, and re-infarction rate. Secondary outcome indicators were the incidence of adverse reactions and the effective rate of traditional Chinese medicine (TCM) treatment. Two independent reviewers will filter the literature and extract data which based to the Cochrane manual. The relevant data, including bias risk assessment, data synthesis, subgroup analysis, meta-analysis, and final meta-analysis, will be analyzed with RevMan 5.3 software. The funnel diagram will be used to evaluate the reported deviation, and the Egger test will be used to evaluate the symmetry of the funnel graph. RESULTS: This systematic review study will provide a clear basis for evaluating the efficacy and safety of Astragalus (Huangqi) preparation with the treatment of AMI. CONCLUSION: This study will provide an up-to-date evidence for evaluating the efficacy and safety of Astragalus (Huangqi) preparation. PROSPERO REGISTRATION NUMBER: CRD42019124843. Wolters Kluwer Health 2019-04-19 /pmc/articles/PMC6494254/ /pubmed/31008964 http://dx.doi.org/10.1097/MD.0000000000015256 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Zhang, Yuqin Wu, Jiani Guo, Shuwen Lin, Wangou Zhang, Binyue Chen, Xi Mo, Hanrong Zhan, Tianwei The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials |
title | The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials |
title_full | The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials |
title_fullStr | The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials |
title_full_unstemmed | The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials |
title_short | The clinical efficacy and safety of the Chinese herbal medicine Astragalus (Huangqi) preparation for the treatment of acute myocardial infarction: A systematic review of randomized controlled trials |
title_sort | clinical efficacy and safety of the chinese herbal medicine astragalus (huangqi) preparation for the treatment of acute myocardial infarction: a systematic review of randomized controlled trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494254/ https://www.ncbi.nlm.nih.gov/pubmed/31008964 http://dx.doi.org/10.1097/MD.0000000000015256 |
work_keys_str_mv | AT zhangyuqin theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT wujiani theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT guoshuwen theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT linwangou theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT zhangbinyue theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT chenxi theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT mohanrong theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT zhantianwei theclinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT zhangyuqin clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT wujiani clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT guoshuwen clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT linwangou clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT zhangbinyue clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT chenxi clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT mohanrong clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials AT zhantianwei clinicalefficacyandsafetyofthechineseherbalmedicineastragalushuangqipreparationforthetreatmentofacutemyocardialinfarctionasystematicreviewofrandomizedcontrolledtrials |